A Long Term Study of STN1012600 in Subjects With Open Angle Glaucoma or Ocular Hypertension
Status:
Recruiting
Trial end date:
2024-01-31
Target enrollment:
Participant gender:
Summary
To evaluate safety and the ocular hypotensive effect of STN1012600 ophthalmic solution 0.002%
alone or in combination with Timolol ophthalmic solution 0.5% for 52 weeks in subjects with
open angle glaucoma or ocular hypertension.